Dr. Robert Melamede, PhD., President & CEO of Cannabis Science, Reports High Level of Media Interest in Public Speaking Engagements, News Interviews, and Corporate Sponsorships at Several Cannabis
COLORADO SPRINGS, Colo. - Dr. Robert Melamede, CEO and President of Cannabis Science, Inc. (OTCBB: CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, was pleased by the intense interest in Cannabis Science exhibited by the attendees of the Colorado Cannabis Convention, where attendance was estimated to have been in the tens of thousands, with over 300 cannabis-related businesses, including Cannabis Science, having booths.
Dr. Melamede explained, "Cannabis Science was presented as a patient-oriented company that works closely with the patient community so as to better understand their needs. We also look to the medical marijuana community as a source of ideas. I especially enjoyed meeting with the patients who came to the Cannabis Science booth and told us how medical cannabis changed their lives."
This week, Friday April 16, Dr. Melamede will be addressing the Sixth National Clinical Conference on Cannabis Therapeutics in Warwick, Rhode Island. The conference is sponsored by Patients Out of Time and the Rhode Island Patient Advocacy Coalition. Dr. Melamede will be speaking on the Endocannabinoid System, by which the human body produces substances similar to the phytocannabinoids found in cannabis. Dr. Melamede will be joining a distinguished roster of speakers that will include Raphael Mechoulam of the Hebrew University in Israel, who will deliver the conference's keynote address.
Dr. Melamede will present his hypotheses that the endocannabinoid system drove the evolution of vertebrates, particularly their immune system, nervous system and consciousness. Furthermore, because of the rapid rate of changes brought on by humans over the past 150 years, low doses of cannabis should now be regarded as an essential nutrient in order to decrease the tonic level of inflammation that is behind age related illnesses by increasing the homeostatic level of human anti-inflammatory cannabinoid activity.
Other topics at the conference include: 'Safety of Medical Cannabis Use;' 'Endocannabinoid System and Neuropathic Pain;' 'Oral Preparations;' 'The Endocannabinoid System and Reproductive Pain;' 'Growing Cannabis for Medicine;' 'Cannabinoid/Opioid Interactions,' and 'Medical Cannabis and the Struggle to Break the NIDA Monopoly.' 'Of particular interest for Cannabis Science will be the presentations by Michael Krawitz and Al Byrne regarding Veterans and Pain, PTSD, and Traumatic Brain Injuries.'
Conference agenda appears online at: http://medicalcannabis.com/Clinical-Conferences/2010-upcoming-conference.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.